Enliven Therapeutics, Inc. ELVN
49.43 USD +4.64 (+10.36%)
At closeNov 6, 2026, 7:58 PM EST
49.75 +0.32 +0.65%
After hours · Nov 6, 7:58 PM ET
44.55 Day range 49.66
14.79 52-week range 62.32
- YTD
- +220.97%
- 1 year
- +170.11%
- Market cap
- 3.64B
- EPS (ttm)
- -1.69
- Shares out
- 73.27M
- Forward P/E
- -21.33
- YTD return
- +220.97%
- 1-year return
- +170.11%
- Volume
- 969.79K
- Avg volume
- 1.34M
- Open
- 46.19
- Previous close
- 44.79
- Day's range
- 44.55 – 49.66
- 52-week range
- 14.79 – 62.32
- Price target
- 74.42 (+50.5%)
- Earnings date
- Mar 2, 2027
YTD +33.89 (+218.08%)
Key statistics
- Enterprise value
- 2.41B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -50.77M
- Total cash
- 884.35M
- Total debt
- 0
- Return on equity
- -16.77%
- Short % of float
- 18.35%
- 50-day average
- 47.48
- 200-day average
- 43.11
Analyst view
Price target (mean) 74.42 +50.5% upside
Now 49.43
- Target (low)
- 69.00
- Target (mean)
- 74.42
- Target (high)
- 82.00
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy3
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 2, 2027
Expected Mar 2, 2027. Consensus EPS estimate -0.5527.
Financials — quick view
ELVN Revenue — quarterly 0
ELVN Net income — quarterly -27.70M
ELVN EPS — quarterly -0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 2, 2027 | Dec 30, 2026 | -0.56 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.44786 | -0.36 | +0.09 | +19.62% |
| Aug 5, 2026 | Jun 30, 2026 | -0.38717 | -0.49 | -0.10 | -26.56% |
| May 7, 2026 | Mar 31, 2026 | -0.44 | -0.38 | +0.06 | +13.64% |
| Mar 3, 2026 | Dec 31, 2025 | -0.42 | -0.48 | -0.06 | -14.29% |
| Nov 12, 2025 | Sep 30, 2025 | -0.43 | -0.32 | +0.11 | +25.58% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Guggenheim | reit | Buy | Buy |
| Oct 19, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 2, 2026 | Morgan Stanley | init | — | Overweight |
| Oct 1, 2026 | JP Morgan | init | — | Overweight |
| Aug 18, 2026 | William Blair | init | — | Outperform |
| Aug 18, 2026 | Barclays | init | — | Overweight |
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- enliventherapeutics.com
News
12 Health Care Stocks Moving In Friday's After-Market Session 
Guggenheim Reiterates Buy on Enliven Therapeutics, Maintains $78 Price Target 
HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73 
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday 
Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70 
JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75 - Reported Earlier, Enliven To Present New ELVN-001 Blood Cancer Trial Data At September Medical Meeting
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says 
William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating - Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78
Your note
Sign in to keep a note on ELVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COLLINS HELEN LOUISE | Officer | Sale | Oct 18, 2026 | 25,000 |
| DERYNCK MIKA K | Director | Sale | Aug 3, 2026 | 0 |
| GARLAND J SCOTT | Director | Sale | Sep 30, 2026 | 0 |
| HEYMAN RICHARD A | Director | Sale | Feb 16, 2026 | 0 |
| HOHL BENJAMIN | Chief Financial Officer | Sale | Oct 18, 2026 | 38,000 |
| KINTZ SAMUEL | Chief Executive Officer | Sale | Nov 16, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.68% | 10,025,017 | 495.54M | Jun 29, 2026 |
| Orbimed Advisors LLC. | 9.25% | 6,776,632 | 334.97M | Jun 29, 2026 |
| Polar Capital Holdings PLC | 8.78% | 6,430,636 | 317.87M | Jun 29, 2026 |
| Blackrock Inc. | 5.95% | 4,359,704 | 215.50M | Jun 29, 2026 |
| Vestal Point Capital, LP | 5.46% | 4,000,000 | 197.72M | Jun 29, 2026 |
| Commodore Capital Lp | 4.47% | 3,275,000 | 161.88M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.57% | 1,883,372 | 93.10M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.06% | 1,508,364 | 74.56M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.75% | 1,280,000 | 63.27M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.71% | 1,250,754 | 61.82M | Aug 30, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.53% | 1,123,263 | 55.52M | Sep 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.10% | 807,329 | 39.91M | Jun 29, 2026 |